These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37081104)

  • 21. Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes.
    Dalli J; Colas RA; Quintana C; Barragan-Bradford D; Hurwitz S; Levy BD; Choi AM; Serhan CN; Baron RM
    Crit Care Med; 2017 Jan; 45(1):58-68. PubMed ID: 27632672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients.
    Ravindran R; O'Connor E; Gupta A; Luciw PA; Khan AI; Dorreh N; Chiang K; Ikram A; Reddy S
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolipidomic profiling reveals an age-related deficiency of skeletal muscle pro-resolving mediators that contributes to maladaptive tissue remodeling.
    Markworth JF; Brown LA; Lim E; Castor-Macias JA; Larouche J; Macpherson PCD; Davis C; Aguilar CA; Maddipati KR; Brooks SV
    Aging Cell; 2021 Jun; 20(6):e13393. PubMed ID: 34075679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The need for precision nutrition, genetic variation and resolution in Covid-19 patients.
    Simopoulos AP; Serhan CN; Bazinet RP
    Mol Aspects Med; 2021 Feb; 77():100943. PubMed ID: 33551236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diversified Effects of COVID-19 as a Consequence of the Differential Metabolism of Phospholipids and Lipid Peroxidation Evaluated in the Plasma of Survivors and Deceased Patients upon Admission to the Hospital.
    Žarković N; Łuczaj W; Jarocka-Karpowicz I; Orehovec B; Baršić B; Tarle M; Kmet M; Lukšić I; Biernacki M; Skrzydlewska E
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis.
    Zhu M; Wang X; Hjorth E; Colas RA; Schroeder L; Granholm AC; Serhan CN; Schultzberg M
    Mol Neurobiol; 2016 May; 53(4):2733-49. PubMed ID: 26650044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.
    Regidor PA; Santos FG; Rizo JM; Egea FM
    Med Hypotheses; 2020 Dec; 145():110340. PubMed ID: 33069094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
    Wu H; Zhu H; Yuan C; Yao C; Luo W; Shen X; Wang J; Shao J; Xiang Y
    JAMA Netw Open; 2020 Jun; 3(6):e2010895. PubMed ID: 32492165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 and cancer: start the resolution!
    Barksdale C; Kipper FC; Tripathy S; Subbian S; Serhan CN; Panigrahy D
    Cancer Metastasis Rev; 2022 Mar; 41(1):1-15. PubMed ID: 35190921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation.
    Pagani L; Chinello C; Risca G; Capitoli G; Criscuolo L; Lombardi A; Ungaro R; Mangioni D; Piga I; Muscatello A; Blasi F; Favalli A; Martinovic M; Gori A; Bandera A; Grifantini R; Magni F
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Simultaneous Extraction/Derivatization Strategy for Quantitation of Vitamin D in Dried Blood Spots Using LC-MS/MS: Application to Biomarker Study in Subjects Tested for SARS-CoV-2.
    Chhonker YS; Ahmed N; Johnston CM; Barnabas RV; Murry DJ
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
    Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
    Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19.
    Soares-Schanoski A; Sauerwald N; Goforth CW; Periasamy S; Weir DL; Lizewski S; Lizewski R; Ge Y; Kuzmina NA; Nair VD; Vangeti S; Marjanovic N; Cappuccio A; Cheng WS; Mofsowitz S; Miller CM; Yu XB; George MC; Zaslavsky E; Bukreyev A; Troyanskaya OG; Sealfon SC; Letizia AG; Ramos I
    Front Immunol; 2022; 13():821730. PubMed ID: 35479098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Inflammatory Effect of Specialized Proresolving Lipid Mediators on Mesenchymal Stem Cells: An In Vitro Study.
    AlZahrani S; Shinwari Z; Gaafar A; Alaiya A; Al-Kahtani A
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The serum amino acid profile in COVID-19.
    Atila A; Alay H; Yaman ME; Akman TC; Cadirci E; Bayrak B; Celik S; Atila NE; Yaganoglu AM; Kadioglu Y; Halıcı Z; Parlak E; Bayraktutan Z
    Amino Acids; 2021 Oct; 53(10):1569-1588. PubMed ID: 34605988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial.
    Prüss H; Rosche B; Sullivan AB; Brommer B; Wengert O; Gronert K; Schwab JM
    PLoS One; 2013; 8(2):e55859. PubMed ID: 23409068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation.
    Weiss GA; Troxler H; Klinke G; Rogler D; Braegger C; Hersberger M
    Lipids Health Dis; 2013 Jun; 12():89. PubMed ID: 23767972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.